FDMT
4D Molecular Therapeutics, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
1.09
P/S
5.68
EV/EBITDA
-2.79
DCF Value
$-10.23
FCF Yield
-22.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
-14.0%
Operating Margin
-187.2%
Net Margin
-164.4%
ROE
-31.7%
ROA
-24.7%
ROIC
-30.2%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $85.1M | $19.4M | $0.34 |
| FY 2025 | $85.2M | $-140.1M | $-2.42 |
| Q3 2025 | $90.0K | $-56.9M | $-1.01 |
| Q2 2025 | $15.0K | $-54.7M | $-0.98 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
2.93
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.